Genome Editing in Drug Discovery
Wiley-Blackwell (Verlag)
978-1-119-67134-3 (ISBN)
In »Genome Editing in Drug Discovery«, a team of distinguished biologists delivers a comprehensive exploration of genome editing in the drug discovery process, with coverage of the technology’s history, current issues and techniques, and future perspectives and research directions. The book discusses techniques for disease modeling, target identification with CRISPR, safety studies, therapeutic editing, and intellectual property issues.
The safety and efficacy of drugs and new target discovery, as well as next-generation therapeutics are also presented.
Offering practical suggestions for practitioners and academicians involved in drug discovery, »Genome Editing in Drug Discovery« is a fulsome treatment of a technology that has become part of nearly every early step in the drug discovery pipeline. Selected contributions also include:
- A thorough introduction to the applications of CRISPRi and CRISPRa in drug discovery
- Comprehensive explorations of genome-editing applications in stem cell engineering and regenerative medicine
- Practical discussions of the safety aspects of genome editing with respect to immunogenicity and the specificity of CRISPR-Cas9 gene editing
- In-depth examinations of critical socio-economic and bioethical challenges in the CRISPR-Cas9 patent landscape
Perfect for academic researchers and professionals in the biotech and pharmaceutical industries, »Genome Editing in Drug Discovery« will also earn a place in the libraries of medicinal chemists, biochemists, and molecular biologists.
Marcello Maresca, PhD, is a Senior Director in the Discovery Sciences Department at AstraZeneca. He obtained his doctorate in Molecular Biology from the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany.
Sumit Deswal, PhD, is an Associate Principal Scientist with the Genome Engineering Team at AstraZeneca R&D in Sweden. He obtained his doctorate in Immunology from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany.
Prelim pages
Contents
Preface ((to follow))
1. Genome editing in drug discovery
2. Historical overview of Genome Editing from bacteria to higher eukaryotes
3. CRISPR Cas: from bacterial adaptive immunity to the swiss army knife of drug discovery
4. Commercial reagents and services for genome editing
5. Computational tools for target design and analysis
6. Genome editing in cellular disease models
7. Utilizing CRISPR/Cas9 technologies for in vivo disease modeling and therapy
8. Pooled CRISPR KO screens for target identification
9. Functional genomics: arrayed CRISPR KO screens
10. Applications of CRISPRi and CRISPRa in drug discovery
11. High throughput targeted mutagenesis by CRISPR-Cas9 base editing
12. Single-cell transcriptomics and epigenomics for CRISPR-mediated perturbation studies
13. DNA repair pathways in the context of therapeutic genome editing
14. DNA base editing strategies for genome editing
15. RNA base editing technologies for gene therapy
16. Genome Editing applications in cancer T Cell Therapy
17. Genome-editing applications in stem cell engineering and regenerative medicine
18. Delivery and Formulation Methods for Therapeutic Genome Editing
19. Safety aspects of genome editing: Immunogenicity
20. Specificity of CRISPR-Cas9 gene editing
21. Key socio-economic and (bio)ethical challenges in the crispr-cas9 patent landscape
22. Future prospects and emerging technologies for genome editing
Subject Index
| Erscheinungsdatum | 10.03.2022 |
|---|---|
| Verlagsort | Hoboken |
| Sprache | englisch |
| Maße | 225 x 285 mm |
| Gewicht | 1174 g |
| Einbandart | gebunden |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Biomedizin |
| Medizin / Pharmazie ► Pharmazie | |
| Naturwissenschaften ► Biologie ► Biochemie | |
| Naturwissenschaften ► Chemie ► Technische Chemie | |
| ISBN-10 | 1-119-67134-5 / 1119671345 |
| ISBN-13 | 978-1-119-67134-3 / 9781119671343 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
